Stephane Bancel, Chief Executive Officer at Moderna, Inc. (MRNA), sold 160,000 shares at $127.53 ($20.4M) on 2023-06-01, disclosed to the SEC on 2023-06-02.
Scheduled sale ($20.4M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $125.38 | 9,478 | $1.2M | 5.8% |
| 2 | $125.38 | 9,478 | $1.2M | 5.8% |
| 3 | $126.71 | 14,636 | $1.9M | 9.1% |
| 4 | $126.71 | 14,636 | $1.9M | 9.1% |
| 5 | $127.84 | 11,036 | $1.4M | 6.9% |
| 6 | $127.84 | 11,036 |
| $1.4M |
| 6.9% |
| 7 | $128.42 | 4,850 | $623K | 3.1% |
| 8 | $128.42 | 4,850 | $623K | 3.1% |
| 9 | $125.96 | 1,410 | $178K | 0.9% |
| 10 | $125.96 | 1,410 | $178K | 0.9% |
| 11 | $127.53 | 8,611 | $1.1M | 5.4% |
| 12 | $127.53 | 8,611 | $1.1M | 5.4% |
| 13 | $128.18 | 29,979 | $3.8M | 18.8% |
| 14 | $128.18 | 29,979 | $3.8M | 18.8% |
| Total | $127.44 avg | 160,000 | $20.4M | 100% |
| Filing → |
| MRNA | SELL | 2024-02-16 | $4.7M | — | Filing → |
| MRNA | SELL | 2023-06-30 | $6.6M | — | Filing → |
| MRNA | SELL | 2023-06-23 | $19.3M | — | Filing → |